The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.

Inclusion Criteria:

• Subjects who previously received and tolerated revusiran (ALN-TTRSC) in the ALN-TTRSC-002 study
• Adequate liver function
• Not Pregnant or nursing

Exclusion Criteria:

• Inadequate renal function
• Uncontrolled hypertension, ischemic heart disease or clinically significant cardiac arrhythmia
• Untreated hypo- or hyperthyroidism
• Prior major organ transplant

All patients who received at least 1 dose of revusiran

All AEs that occurred after the start of study drug administration on Day 0 (Baseline) up to 90 days post modified early termination visit (End of Study); Mean duration of collection was 16 months.

The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study

Safety and efficacy data are difficult to interpret due to the limited numbers of patients completing the study.